Opko Health Inc (OPK)

[midastouch017]

Guggenheim Starts Opko Health (OPK) at Buy, "Dr. Frost Brings Some Virtue to Miami Vice"

Guggenheim initiates coverage on Opko Health (NASDAQ: OPK) with a Buy rating and a price target of $25.00.

Analyst Louise Chen comments "We believe OPK’s evolution from a diagnostic company to a diagnostic and pharmaceutical company focused on urology, nephrology and other therapeutic areas is underappreciated. The story is complex and under-owned by institutional investors. Therefore, we expect upwards earnings revisions to levels not reflected in consensus and multiple expansion (from diagnostic to hybrid diagnostic/pharma multiple) to drive shares higher."

For an analyst ratings summary and ratings history on Opko Health click here. For more ratings news on Opko Health click here.

https://www.streetinsider.com/Analyst+Comments/Guggenheim+Starts+Opko+Health+(OPK)+at+Buy,+%22Dr.+Frost+Brings+Some+Virtue+to+Miami+Vice%22/12664257.html